JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB252736

Anti-Clostridium botulinum toxin A antibody [B365M]

Be the first to review this product! Submit a review

|

(1 Publication)

Mouse Monoclonal BXA1 antibody. Suitable for ICC, ELISA, IF, RIA and reacts with Clostridium botulinum samples. Cited in 1 publication.

View Alternative Names

atx, bonT, botA, Botulinum neurotoxin type A, BoNT/A, Bontoxilysin-A, Botulinum neurotoxin type A1, BOTOX

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

B365M

Isotype

IgG

Carrier free

No

Reacts with

Clostridium botulinum

Applications

RIA, IF, ICC, ELISA

applications

Specificity

Binds to intact whole C. botulinum Toxin A, amino acids 1280-1292. Has been found to stain Neuro2A cells treated with GT1b ganglioside prior to the addition of C. botulinum Toxin A. Inhibits the entry of C. botulinum Toxin A to Neuro2A cells treated with GT1b ganglioside prior to the addition of the toxin.

Cross-Reactivity:
C. botulinum Toxin A (1280-1292) 100%
C. botulinum Toxin A 100%
C. botulinum Toxin B 0%
C. botulinum Toxin C 0%
C. botulinum Toxin E 0%
C. botulinum Toxin F (1272-1280) 0%.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICC" : {"fullname" : "Immunocytochemistry", "shortname":"ICC"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "IF" : {"fullname" : "Immunofluorescence", "shortname":"IF"}, "RIA" : {"fullname" : "Radioimmunoassay", "shortname":"RIA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Clostridium botulinum": { "ICC-species-checked": "guaranteed", "ICC-species-dilution-info": "1/50", "ICC-species-notes": "<p></p>", "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>", "IF-species-checked": "guaranteed", "IF-species-dilution-info": "", "IF-species-notes": "<p></p>", "RIA-species-checked": "guaranteed", "RIA-species-dilution-info": "", "RIA-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purity
Tissue culture supernatant
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Clostridium botulinum toxin A also known as botulinum toxin or Botox is a neurotoxic protein produced by the bacterium Clostridium botulinum. The toxin has a molecular mass of approximately 150 kDa and is synthesized by the bacteria under anaerobic conditions. It functions by cleaving SNAP-25 a protein essential for neurotransmitter release at the neuromuscular junction effectively blocking acetylcholine release and leading to flaccid paralysis. This action occurs in the peripheral nervous system where the toxin is expressed.
Biological function summary

Botulinum toxin disrupts synaptic transmission by targeting the SNARE complex which includes proteins like syntaxin and VAMP. It does not work alone rather it acts as part of a larger system that involves several molecular machinery components. The toxin enters nerve cells via receptor-mediated endocytosis and interrupts communication between nerves and muscles. This interaction results in muscle relaxation explaining its use in both medical and cosmetic fields.

Pathways

The nerve blocking mechanism of botulinum toxin interferes with the cholinergic signaling pathway. This pathway relies on the proper function of SNARE proteins to facilitate synaptic vesicle fusion. By targeting these SNARE proteins botulinum toxin effectively halts neurotransmitter release. The toxin's effects relate to similar mechanisms associated with other neurotoxins and synaptic proteins like tetanus toxin which also affects the SNARE complex but has a different clinical outcome.

Botulinum toxin is linked to botulism a severe form of muscle paralysis. This disorder arises from the toxin's ability to inhibit neurotransmission. The condition requires immediate diagnosis and treatment often using antitoxins to prevent severe complications. Additionally botulinum toxin has therapeutic uses in treating conditions like chronic migraine and spasticity exploiting its muscle-relaxing properties. These clinical applications emphasize the toxin’s dual role in pathology and therapy showcasing its significant impact on human health.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Botulinum neurotoxin type A. Botulinum toxin causes flaccid paralysis by inhibiting neurotransmitter (acetylcholine) release from the presynaptic membranes of nerve terminals of the eukaryotic host skeletal and autonomic nervous system, with frequent heart or respiratory failure (PubMed : 15394302, PubMed : 7578132). Precursor of botulinum neurotoxin A which has 2 coreceptors; complex polysialylated gangliosides found on neural tissue and specific membrane-anchored proteins of synaptic vesicles. Receptor proteins are exposed on host presynaptic cell membrane during neurotransmitter release, when the toxin heavy chain (HC) binds to them. Upon synaptic vesicle recycling the toxin is taken up via the endocytic pathway. When the pH of the toxin-containing endosome drops a structural rearrangement occurs so that the N-terminus of the HC forms pores that allows the light chain (LC) to translocate into the cytosol (PubMed : 17666397, PubMed : 19096517). Once in the cytosol the disulfide bond linking the 2 subunits is reduced and LC cleaves its target protein on synaptic vesicles, preventing their fusion with the cytoplasmic membrane and thus neurotransmitter release. Toxin activity requires polysialylated gangliosides; GT1b supports activity better than GD1a (PubMed : 12089155). Binds to host peripheral neuronal presynaptic membranes via the synaptic vesicle glycoproteins SV2A, SV2B and SV2C (PubMed : 16543415). It binds directly to the largest lumenal (intravesicular) loop of SV2A, SV2B and SV2C that is transiently exposed outside of cells during exocytosis; gangliosides enhance binding (PubMed : 16543415, PubMed : 16545378, PubMed : 18815274). Recognizes an N-linked glycan on SV2 proteins (PubMed : 18815274, PubMed : 27294781). May also use FGFR3 as a receptor (PubMed : 23696738). Toxin uptake into neural cells requires stimulation (incubation with K(+) to stimulate receptor exposure) to be internalized by receptor-mediated endocytosis (PubMed : 16543415, PubMed : 19650874, PubMed : 21632541, PubMed : 21832053). Subsequently the toxin colocalizes with its receptor in host cells (PubMed : 16543415, PubMed : 19650874). Toxin uptake can be blocked by the appropriate SV2 protein fragments in cell culture (PubMed : 16543415).. Botulinum neurotoxin A light chain. Has proteolytic activity (PubMed : 7578132). After translocation into the eukaryotic host cytosol LC hydrolyzes the '197-Gln-|-Arg-198' bond in SNAP25, blocking neurotransmitter release (PubMed : 10694409, PubMed : 11700044, PubMed : 11827515, PubMed : 19351593, PubMed : 7578132, PubMed : 8243676, PubMed : 9886085). Recognizes the '146-Met--Gly-155' region of SNAP25, which confers substrate specificity (PubMed : 15592454, PubMed : 9886085). Hydrolyzes the '202-Thr-|-Arg-203' bond of mouse SNAP23, but not in human which has a different sequence (PubMed : 9886085). Reduction of the interchain disulfide bond occurs in the host cytosol and probably prevents retrotranslocation into the synaptic vesicle (PubMed : 17666397). Has slow (occurs over 4 weeks) autocatalytic cleavage, however it is not clear if this is physiologically relevant (PubMed : 11565902).. Botulinum neurotoxin A heavy chain. Responsible for host epithelial cell transcytosis, host nerve cell targeting and translocation of botulinum neurotoxin A light chain (LC) into host cytosol. Composed of 3 subdomains; the translocation domain (TD), and N-terminus and C-terminus of the receptor-binding domain (RBD) (PubMed : 19096517). The RBD is responsible for binding to host epithelial cells and transcytosis across them; this uses different receptors than those on nerve cells (PubMed : 21106906). RBD is also responsible for adherence of toxin to host nerve cell surface; HC alone prevents uptake of whole toxin by neural cells, and delays paralysis onset by 75% (PubMed : 10413679, PubMed : 6694738). Isolated RBD also delays paralysis onset (PubMed : 21106906). The N-terminus of the RBD binds to phosphatidylinositol, which might play a role in membrane-binding (PubMed : 19161982). Binds to host protein receptor synaptic vesicle glycoproteins SV2A, SV2B and SV2C via lumenal loop 4 (PubMed : 16545378, PubMed : 19650874, PubMed : 24240280, PubMed : 27294781, PubMed : 27313224, PubMed : 6370252). Binding can be inhibited by protein fragments from either the HC or SV2C (PubMed : 24240280). Isolated HC significantly decreases uptake and toxicity of whole BoNT/A, but also interferes with uptake of BoNT/E and to a lesser extent BoNT/F (PubMed : 19650874). The RBD recognizes the N-linked glycan on 'Asn-559' of SV2A, SV2B and SV2C; hydrogen-bonding occurs via 10 well-defined water molecules and stacking of hydrophobic residues (PubMed : 27294781). Binds one host GT1b ganglioside, which serves as a coreceptor (PubMed : 14731268, PubMed : 18704164, PubMed : 27958736). Modeling shows the HC can bind both coreceptors (a ganglioside and SV2 protein) simultaneously at different sites (PubMed : 24240280). Crystals of the RBD with a GT1b analog can be grown at pH 5.5, indicating the toxin-ganglioside complex could be stable within the endosome (PubMed : 18704164). Isolated RBD binds NTNHA (a bacterial protein that protects toxin) with high affinity at pH 6.0 but not at pH 7.5 (PubMed : 22363010). The N-terminal belt (residues 449-545) wraps around the perimeter of the LC, probably protecting Zn(2+) in the active site; it is not required for channel formation by the TD domain but may serve to prevent premature LC dissociation from the translocation channel and to protect toxin prior to translocation (PubMed : 17907800, PubMed : 19351593, PubMed : 22158863). The isolated TD forms transmembrane channels of about 15 Angstroms in the absence of a pH gradient; LC translocation requires a pH and redox gradient (pH 5.0/oxidizing in the cis compartment, pH 7.0/reducing in the trans compartment), LC does not unfold unless the cis pH is 6.0 or less (PubMed : 17666397, PubMed : 19096517, PubMed : 2446925). Pores are presumably made by 1-2 toxin molecules (PubMed : 23471747). While interaction with the RBD modulates the pH threshold for membrane insertion, the RBD is not essential for toxin degradation of SNAP25 in neural cells (PubMed : 19096517).
See full target information botA

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Current protocols 4:e1030 PubMed38923763

2024

Applications of Surface Plasmon Resonance (SPR) to the Study of Diverse Protein-Ligand Interactions.

Applications

Unspecified application

Species

Unspecified reactive species

Dana M Burris,Samuel W Gillespie,Emma Joy Campbell,S Nick Ice,Vikas Yadav,William D Picking,Christian L Lorson,Kamal Singh
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com